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Naturally acquired anti-Pseudomonas aeruginosa antibody fails to afford protection against
repeated P. aeruginosa bronchopulmonary exacerbations in cystic fibrosis (CF) patients. In an
effort to explain this phenomenon, the titer and affinity constants of serum anti-lipopolysaccha-
ride (LPS) IgG were determined in five study groups: healthy adults before and after immuniza-
tion with a polyvalent LPS-based vaccine, healthy noncolonized CF patients before and after
immunization, nonimmunized CF patients with significantly elevated anti-LPS antibody titers
without documented colonization, recently colonized CF patients before and after immuniza-
tion, and nonimmunized CF patients chronically colonized with P. aeruginosa. Immunization
elicited a significant rise in total anti-LPS immunoglobulin levels and affinity constants in both
healthy adults and CF patients. Although chronically colonized patients had elevated levels of
total anti-LPS antibody, these antibodies possessed affinities at least tOO-fold less than those of
vaccine-induced antibodies.
Bronchopulmonary infections due to Pseudomonas aeru-
ginosa are a leading cause of morbidity and mortality among
cystic fibrosis (CF) patients [I]. Overt disease caused by
rough mucoid strains ofP. aeruginosa is preceded by coloni-
zation of the upper respiratory tract with smooth strains [2].
Colonization and pulmonary exacerbations stimulate a rise
in serum antibody levels to a number of somatic and extra-
cellular antigens including lipopolysaccharide (LPS), algin-
ate, and toxin A [3, 4]. Such antibodies do not appear to
prevent or ameliorate subsequent infections.
Several laboratories have found a positive correlation be-
tween severe disease and elevated anti-P, aeruginosa anti-
body levels [5, 6]. In addition, circulating immune com-
plexes formed during pulmonary exacerbations may
contribute substantially to organ damage [6, 7]. The above
has led to the belief that such antibodies are detrimental to
the host, although the precise reason such antibodies are not
protective is not known. The most widely held belief is that
most naturally acquired antibodies possess a greatly reduced
opsonic capacity [8, 9]. However, serum from colonized CF
patients can protect mice against experimental P. aeruginosa
when passively transferred [5]. Furthermore, recent studies
have found that CF serum can support the uptake ofP. aeru-
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ginosa by polymorphonuclear leukocytes from healthy
adults [8]. Therefore, at least a subpopulation of naturally
acquired antibodies possess functionally relevant traits;
A number ofapproaches, including immunization, are be-
ing evaluated in an effort to control recurrent P. aeruginosa
infections in CF patients [10-12]. Ofcritical importance is to
establish the long-term safety ofsuch vaccines and to demon-
strate that immunization engenders antibodies with desired
functional attributes. We have recently described the safety
and immunogenicity of an octavalent O-polysaccharide-
toxin A conjugate vaccine in young noncolonized CF pa-
tients [13]. In the present study we compared the affinity
constants of naturally acquired and vaccine-induced anti-
LPS antibodies.
Materials and Methods
Vaccine. The synthesis, safety, and immunogenicity of the
polyvalent P. aeruginosa a-polysaccharide-toxin A conjugate
vaccine have been described previously [14, 15]. Each dose con-
tained 25 #Lg of a-polysaccharide of the following international
antigen typing serotypes (lATS): I, 2, 3, 4, 6, 7, 10, and II.
LPS. LPS from P. aeruginosa PA220 (lATS 6) and P. aeru-
ginosa 27313 (lATS II) was isolated as described [16]. The LPS
preparations contained <2% (wt/wt) protein and nucleic acid.
Determination ofanti-LPS antibody titers. Serum antibodies
specific for LPS were quantitated by ELISA as described else-
where [5, 17, 18]. For coating, purified LPS (5 mg/rnl) dissolved
in 36 mM triethylamine was used. Microtiter plates (Irnmulon:
Dynatech, Buchs, Switzerland) were used for incubation; each
well contained 100 #LI of a solution of I #Lg of LPSjml of 0.1 M
sodium carbonate buffer, pH 9.6.
Determination ofantibody affinities. Apparent affinity con-
stants were obtained by ELISA-based determinations of the re-
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ciprocal of the molar antigen concentration resulting in 50%
inhibition of antibody binding. Serum samples were titrated in
PA220 LPS-coated microtiter plates as described above, and
dilutions resulting in an 00 of0.8-1.2 were used. The percent-
age of binding in the presence of LPS was determined by
extrapolation to a standard curve constructed from parallel ex-
periments with known percentages of the concentration ofanti-
bodies used in the inhibition experiments [19]. The concentra-
tion of LPS resulting in 50%inhibition of the antibody binding
was determined as described by Reed and Muench [20]. The
affinity constants of monoclonal antibodies determined by this
method have been shown to be in close agreement with the
intrinsic affinity constant measured by Farr assay and fluores-
cence quenching assays [21]. Calculations of the molar concen-
trations were based on the assumed molecular weight of 10,000
for LPS as described by Schwartzer et al. [22].
The range of detectable affinities in polyclonal sera depends
on the concentration of the antigen in the solid phase [23]. A
concentration of PA220 LPS (1 JLgjml) was chosen, which al-
lowed the detection of antibodies over a range of 104 to
>10 8 M- 1•
The specificity of this assay system was verified with monoclo-
nal antibodies specific for P. aeruginosa LPS [17, 18]. Only anti-
bodies specific for IATS 6 LPS or those that recognize antigenic
determinants common to most serotypes of P. aeruginosa LPS
gave a signal in this assay system.
Patients and clinical studies. CF patients were enrolled from
those attending the CF clinic at the Inselspital. Healthy adults
were staff members at the Tiefenau Hospital, Berne. Radiologic
and pulmonary scores (Crispin-Norman and Bernese) and co-
lonization with P. aeruginosa were determined at the time of
immunization and at yearly intervals thereafter as previously
described [5]. A patient classified as colonized had P. aeruginosa
isolated from sputum or saliva samples on multiple occasions for
at least 5 years before entry into this study. A patient was classi-
fied as noncolonized when three conditions were met: no history
of P. aeruginosa isolated from either sputum or saliva samples,
no overt bronchopulmonary infection attributable to P. aerugin-
osa, and possession oflow IgG antibody levels to nine serotypes
of P. aeruginosa LPS frequently associated with infections in CF
patients and to exotoxin A. The mean ages (ranges) for the pa-
tient groups were as follows: noncolonized immunized, 6.3
years (2-11); colonized nonimmunized, 13.2 (7-22); "ques-
tionably" colonized (significantly elevated anti-LPS antibody
titers without documented colonization), 18.5 (6.5-30); colon-
ized immunized, 8.5 (7-9).
Healthy subjects received a vaccine dose equal to 25 JLg of0-
polysaccharide per vaccine serotype (200 JLg total) on days 0 and
28. CF patients received 12.5 JLg of a-polysaccharide per vac-
cine serotype on days 0 and 56. The vaccine was administered
intramuscularly in the deltoid area in 0.5 ml of vehicle. Serum
samples were collected 2-4 weeks after each immunization.
Clinical scores for CF patients were obtained at the time of pri-
mary immunization.
Opsonophagocytic assay. The ability of sera from CF pa-
tients to support the uptake and killing of P. aeruginosa PA220
(IATS 6) by polymorphonuclear leukocytes from healthy adults
was measured as described elsewhere [10] with the following
modifications. The final concentration of normal human serum
was 1%and the sampling times were at 0 and 90 min. Test sera
were evaluated at the following dilutions: 1:12, 1:36, 1:108,
1:324, and 1:972. Opsonic titer was defined as the reciprocal of
the highest dilution of serum that resulted in ~70% killing of the
initial bacterial inoculum.
Statistical analysis. Significance between IgG ELISA titers
and affinity constants before and after immunization was deter-
mined by the paired t test. Significance between immunized and
nonimmunized groups was determined by the single-tailed t test
for groups.
Results
Characteristics of the five study groups are shown in table
1. The IATS 6 LPS was selected as representative antigen for
the following reasons: it is the predominating serotype of P.
aeruginosa associated with pulmonary infections at the Insel-
spital CF Clinic, all colonized CF patients had elevated anti-
IATS 6 LPS antibody, and the IATS 6 vaccine component
was found to be highly immunogenic in healthy adults and
CF patients. Healthy adults had low levels (mean titer, 67) of
naturally acquired anti-LPS antibodies. Noncolonized CF pa-
tients, whose mean antibody titer was comparable to that of
healthy adults, had clinical scores within the normal range.
A group of 6 CF patients was included in this study whose
colonization statuses were unclear (questionably colonized).
Although P. aeruginosa was never isolated, all had elevated
IgG antibody titers to a bank of nine P. aeruginosa LPS anti-
gens including IATS 6 (mean titer, 970), strongly suggestive
of prior subclinical exposure or current low-level coloniza-
tion. In addition, their baseline clinical scores fell between
those of noncolonized and colonized CF patients. Also in-
cluded were 2 patients recently colonized with IATS 6 P.
aeruginosa (4-5 months before immunization). The final
group was 8 patients colonized for a mean of 6.4 years. This
group had markedly reduced clinical scores and elevated
anti-IATS 6 LPS IgG antibody titers.
Local reactions, characterized by pain and swelling at the
injection site, were classified as mild to moderate and were
associated with roughly half of the vaccinations. Reactions
manifested by the 2 colonized patients who were immunized
were similar in severity and duration to those observed for
the noncolonized patients. No systemic reactions were re-
ported.
The anti-IATS 6 immune response to immunization with
the P. aeruginosa polyvalent vaccine and affinity constants
for baseline and postimmunization serum samples are shown
in table 2. Immunization of healthy adults or noncolonized
CF patients resulted in a significant (P < .05) rise in IgG
antibody levels. There was no difference in the magnitude of
the immune response between these two groups (P> .05).
The 2 newly colonized CF patients (whose baseline titers
were similar to those of the above groups) also responded
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Table 1. Clinical characteristics of study groups.
Mean base clinical score (range)
JID 1992; 166 (August)
Group (n)
Healthy adults, noncolonized, immunized (6)
CF patients
Noncolonized, immunized (7)
Questionably colonized, nonimmunized (6)
Colonized 0.4 years. immunized (2)
Colonized 6.4 years, nonimmunized (8)
Bernese
NO
23.1 (22-24)
20.7 (16-24)
23.5 (23. 24)
14.3 (11-20)
Crispin-Norman
NO
4.8 (3-8)
8.2 (4-13)
4.0
15.9 (8-21)
Mean baseline IgG
titer (range)
67 «40-350)
31 «40-130)
970 (146-7166)
60
2108 (1086-10.347)
NOTE. Baseline titers are at time of enrollment into study for those nonimmunized or at time ofimmuniza-
tion. NO = not determined. Questionably colonized: significantly elevated antibody titers without documented
colonization.
with a vigorous antibody response to vaccination. Subjects in
all three groups had extremely low baseline affinity constants
(::::;0.02 X 106 M-1) . The mean affinity constant for normal
adults and non colonized CF patients increased > 10,000-
fold after immunization (P < .00 I). Both newly colonized
patients responded with a pronounced rise in affinity after
immunization.
Chronically colonized and questionably colonized CF pa-
tients had baseline anti-IATS 6 antibody titers significantly
higher (P < ,05) than those of healthy adults or noncolon-
ized patients. Furthermore, their baseline titers exceeded
those attained by healthy adults and noncolonized patients
after immunization. Baseline affinity constants for this
chronically colonized group were significantly higher (P
= .027) than baseline levels for either healthy adults or
noncolonized patients, while a similar comparison for the
questionably colonized group approached significance (P
= .077).
Immunized healthy adults or noncolonized CF patients
possessed mean affinity constants at least 35-fold higher than
those seen for colonized patients (P < .00 I). Both recently
colonized CF patients also showed a marked increase
(> IOOO-fold) in antibody affinity after immunization. A simi-
lar trend was seen when IATS II LPS was used as a test
antigen (data not shown).
It was of interest to determine if the induction of high-af-
finity antibody by vaccination was associated with an in-
crease in functional capacity. Therefore, sera from nonco-
Ionized immunized patients and colonized nonimmunized
patients with high levels of anti-IATS 6 IgO antibody were
tested for their ability to promote the opsonophagocytic kill-
ing of an IATS 6 strain of P. aeruginosa (table 3). The sera
from only 2 of 8 colonized patients were able to promote the
uptake and killing of the test strain, whereas sera from all 3
immunized patients expressed opsonic activity. The ratio of
antibody to opsonic titer for immunized patients and for co-
lonized nonimmunized patients ranged from 12 to 18 and
from 55 to >446, respectively. These data indicate that the
high-affinity antibody induced by vaccination possesses the
desired functional attributes.
The kinetics of the immune response induced by vaccina-
tion pertaining to both IgO antibody titer and mean affinity
constant was studied. Sequential serum samples were avail-
able for I patient who became colonized with an IATS 6 P.
Table 2. Anti-P. aeruginosa (international antigen typing serotype 6) IgG antibody response and
affinity after vaccination and iriduced naturally.
Geometric mean IgG titer (range) Mean affinity constant (range)
After second After second
Group Baseline immunization Baseline immunization
Healthy adults 67 «40-350) 561 (78-1500) 0.02 «0.01-0.01) 238 (50-650)
CF patients
Noncolonized 31 «40-130) 432 ( 100-2060) <0.01 332 (110-640)
Newly colonized 60 2465 (1280, 3650) <0.01 319 (220, 417)
Questionably colonized 970 (146-7166) NA 1.1 «0.01-18.0) NA
Chronically colonized 2108 ( 1086-10,347) NA 6.3 ( 1.1-49.0) NA
NOTE. Affinity constants are X 106 M- 1• NA = not applicable (groups were not immunized). Questionably
colonized: significantly elevated antibody titers without documented colonization.
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sonic and nonopsonic antibodies, with the latter predominat-
ing in most individuals [8, 26]. Nonopsonic antibodies are
believed to contribute substantially to bronchopulmonary
disease in CF by recruitment of inflammatory cells or by
immune complex formation [7, 8, 27, 28]. However, some
CF patients can mount what appears to be a protective op-
sonic antibody response [26]. If this is indeed the case, immu-
nologic intervention in the form of immunization may be of
benefit provided that antibodies expressing the desired func-
tional attributes can be engendered.
Several possible mechanisms have been proposed to ex-
plain the CF opsonic defect. Fick et al. [29] have proposed
that opsonization is compromised by a weak interaction be-
tween antibody and Fe receptors expressed by phagocytic
cells. Moss and coworkers [30, 31] have noted an altered
antibody isotype distribution in CF patients. Certain isotypes
of antibody, specifically IgG2, were found to be far more
efficient at opsonizing both mucoid and nonmucoid P. aeru-
ginosa [8].
The functional traits expressed by a given antibody will be
determined not only by its epitope specificity and isotype but
also by its affinity [32]. High-affinity antibodies are far more
effective than low-affinity antibodies at binding complement
[33]. This may be of considerable significance since opsorto-
phagocytic killing ofmucoid and nonmucoid P. aeruginosa is
a complement-dependent process [34, 35]. Previous data
suggesting that anti-P. aeruginosa antibodies from CF pa-
tients may not interact properly with Fe receptors on phago-
cytic cells [29] prompted us to investigate the affinity ofanti-
Figure 1. Antibody titers (8) and affinities (.) of an immunized
CF patient with previous infection. International antigen typing
serotype 6 P. aeruginosa was detected 5 months (-5) before pri-
mary immunization (0). A secondary vaccination was administered
2 months later.
1000
2000
3000
4000
Table 3. Opsonophagocytic killing of P. aeruginosa (interna-
tional antigen typing serotype 6) mediated by serum from immu-
nized noncolonized and nonimmunized colonized CF patients.
Ratio
Anti-LPS IgG Opsonic antibody titer/
Group. subject antibody titer titer" opsonic titer:
Colonized nonimmunized
I 10.347 36 287
2 1086 <12 >91
3 4302 <12 >359
4 2518 <12 >210
5 2622 <12 >222
6 2723 <12 >227
7 5347 <12 >446
8 1972 36 55
Noncolonized immunized
I 200 12 17
2 1300 12 12
3 210 108 18
* Samples from immunized patients were obtained -- I month after sec-
ond immunization (average of three independent determinations). LPS =
lipopolysaccharide.
t Expressed as reciprocal of highest dilution of serum resulting in ~70%
killing.
t Derived by dividing antibody titer by opsonic titer.
aeruginosa and elected to be vaccinated -.. 5 months later
(figure 1). Anti-LPS IgG antibody titer did not increase dur-
ing the first 5 months of colonization, although nonmucoid
P. aeruginosawas repeatedly obtained from sputum cultures
during this time. Before immunization, this patient's affinity
constant remained at <0.1 X 106 M- 1• Immunization
evoked a parallel rise in IgG ELISA titer and affinity con-
stant, although the latter was far more pronounced. After
primary immunization, the IgG ELISA titer increased from
110 to 280, while affinity rose from <0. 1 to 21 X 106 M -I . A
booster dose of vaccine resulted in a further substantial rise
in both parameters.
The 7 immunized noncolonized patients have been fol-
lowed for 25-28 months after vaccination. All remain non-
colonized, and there was no significant change in their clini-
cal scores. Similarly, no change in clinical status was
observed for the 2 colonized patients who were immunized.
Discussion
Patients with CF have an opsonic defect specific for P.
aeruginosa that extends to blood-derived polymorphonu-
clear leukocytes and lung macrophages [24, 25]. This defi-
ciency is at least partly responsible for the observation that
CF patients experience repeated pulmonary exacerbations
even when possessing high levels of anti-P. aeruginosa anti-
bodies.
Naturally acquired anti-LPS and anti-alginate antibodies
in CF patients consist of a heterogeneous population of op-
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LPS antibodies. The fact that we had access to serum derived
from CF patients immunized with an LPS-based conjugate
vaccine gave us the unique opportunity to compare the affin-
ities of naturally acquired and vaccine-induced antibodies.
Healthy adults and non colonized CF patients possessed
low baseline levels ofanti-IATS 6 antibodies with low mean
affinity constants. Immunization engendered an 8- to 14-
fold rise in IgG titer but a 10,000-fold rise in mean affinity.
The immune response in both groups was comparable, indi-
cating that noncolonized CF patients can respond ade-
quately to a parenterally administered P. aeruginosa LPS-
based vaccine. Two patients recently colonized with IATS 6
P. aeruginosa also responded to vaccination with high-affin-
ity antibodies. Even though postimmunization serum from
healthy adults or CF patients contained somewhat lower to-
tal IgG levels than seen in serum from non vaccinated colon-
ized CF patients, mean affinity constants for the former
groups were significantly higher. The ratio of IgG titer to
mean affinity constant was 334: I for colonized patients and
2.3: I and 1.3: I for postimmunization sera from healthy
adults and noncolonized patients, respectively. Therefore, it
appears that a far greater proportion ofvaccine-induced anti-
bodies than of those acquired after colonization or infection
are of high affinity.
Such high-affinity antibodies appear to mediate the opson-
ophagocytic killing of P. aeruginosa. The sera from all 3 im-
munized noncolonized patients supported the uptake and
killing ofan IATS 6 test strain, whereas the sera from only 2
of the 8 nonimmunized chronically colonized patients did
so. Numerous prior studies have documented a defect in the
ability of CF sera to promote opsonophagocytic killing of P.
aeruginosa [8, 9, 24]. Although the nature of this defect is not
precisely known, it can apparently be overcome by inducing
antibody through vaccination.
CF patients appear to have no innate defect in their ability
to produce high-affinity anti-LPS antibodies. This would
suggest that the route by which the immune system is stimu-
lated is of critical importance. Repeated persistent exposure
to P. aeruginosa in the respiratory tract does not appear to
routinely engender high-affinity antibodies. It is important to
note that 2 of 8 chronically colonized patients did possess an
intermediate mean affinity constant (25-50 X 106 M-1) .
This may indicate a slow maturation ofhigh-affinity antibod-
ies in this patient population, since these patients had been
colonized the longest. Thus, one may speculate that the early
development ofopsonic high-affinity antibodies leads to pro-
tection against P. aeruginosa infection among a subgroup of
CF patients [26]. However, most CF patients produce low-
affinity nonopsonic antibodies after early exposure to P. aer-
uginosa, which would not prevent colonization or subse-
quent infection.
The above findings may have an important bearing on the
potential of active immunization to prevent P. aeruginosa
infections in CF patients. The a-polysaccharide-toxin A
vaccine was capable of stimulating a rapid rise in hi~h-affin­
ity and opsonic antibodies in young noncolonized CF pa-
tients. Booster doses ofvaccine resulted in a rise in both total
anti-LPS IgG antibody and mean affinity constant without a
detrimental effect on clinical status. Vaccination induced
primarily IgG I and IgG2 anti-LPS antibodies (unpublished
data), which are capable of supporting opsonophagocytosis
of P. aeruginosa. Use of such a vaccine, which engenders
functional antibody, may circumvent potential hazards asso-
ciated with the immunization of CF patients [6, 7, II].
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